High Concentration Formulations of Recombinant Human Interleukin-1 Receptor Antagonist: II. Aggregation Kinetics-Reference-Cited by-同舟云学术

High Concentration Formulations of Recombinant Human Interleukin-1 Receptor Antagonist: II. Aggregation Kinetics

Published:2008-08 Issue:8 Volume:97 Page:3005-3021
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Alford John R.,Kendrick Brent S.,Carpenter John F.,Randolph Theodore W.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference29 articles.

1. The development of stable protein formulations—A close look at protein aggregation, deamidation, and oxidation;Cleland;Crit Rev Ther Drug Carrier Syst,1993

2. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation;Chi;Pharm Res,2003

3. Stability of protein pharmaceuticals;Manning;Pharm Res,1989

4. Effects of protein aggregates: An immunological perspective;Rosenberg;AAPS J,2006

5. Challenges in the development of high protein concentration formulations;Shire;J Pharm Sci,2004

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidation of the Reversible Self-Association Interface of a Diabody–Interleukin Fusion Protein Using Hydrogen-Exchange Mass Spectrometry and In Silico Modeling;Molecular Pharmaceutics;2024-06-26

2. From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategies;International Journal of Pharmaceutics;2023-10

3. Comparative Thermodynamics of the Reversible Self-Association of Therapeutic mAbs Reveal Opposing Roles for Linked Proton- and Ion-Binding Events;Pharmaceutical Research;2023-03-03

4. Innovation in Stabilization of Biopharmaceuticals;Recent Advances in Pharmaceutical Innovation and Research;2023

5. Amyloidogenesis: What Do We Know So Far?;International Journal of Molecular Sciences;2022-11-12